Insider Selling: Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) CAO Sells $33,351.28 in Stock

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) CAO James George Chopas sold 1,096 shares of the firm’s stock in a transaction dated Wednesday, January 22nd. The shares were sold at an average price of $30.43, for a total value of $33,351.28. Following the completion of the sale, the chief accounting officer now directly owns 48,138 shares in the company, valued at approximately $1,464,839.34. The trade was a 2.23 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

James George Chopas also recently made the following trade(s):

• On Friday, January 17th, James George Chopas sold 715 shares of Apellis Pharmaceuticals stock. The shares were sold at an average price of $29.96, for a total transaction of $21,421.40.
• On Monday, January 13th, James George Chopas sold 783 shares of Apellis Pharmaceuticals stock. The stock was sold at an average price of $28.70, for a total transaction of $22,472.10.

Apellis Pharmaceuticals Stock Down 2.5 %

NASDAQ APLS opened at $30.00 on Friday. Apellis Pharmaceuticals, Inc. has a 1 year low of $24.34 and a 1 year high of $71.90. The stock has a market capitalization of $3.73 billion, a PE ratio of -14.78 and a beta of 0.94. The company has a debt-to-equity ratio of 1.91, a current ratio of 4.36 and a quick ratio of 3.73. The business’s 50-day moving average is $32.08 and its 200 day moving average is $33.15.

Apellis Pharmaceuticals (NASDAQ:APLS) last posted its earnings results on Tuesday, November 5th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by ($0.14). Apellis Pharmaceuticals had a negative net margin of 34.97% and a negative return on equity of 103.11%. The business had revenue of $196.83 million for the quarter, compared to analysts’ expectations of $200.00 million. During the same period last year, the firm posted ($1.17) earnings per share. Apellis Pharmaceuticals’s quarterly revenue was up 78.3% on a year-over-year basis. Sell-side analysts forecast that Apellis Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Analyst Ratings Changes

Several brokerages recently issued reports on APLS. Wells Fargo & Company cut their target price on shares of Apellis Pharmaceuticals from $43.00 to $30.00 and set an “equal weight” rating for the company in a research report on Wednesday, November 6th. Bank of America cut their price objective on Apellis Pharmaceuticals from $61.00 to $47.00 and set a “buy” rating for the company in a report on Wednesday, November 6th. Mizuho decreased their price objective on Apellis Pharmaceuticals from $39.00 to $38.00 and set a “neutral” rating on the stock in a report on Thursday, October 24th. Oppenheimer cut their target price on Apellis Pharmaceuticals from $65.00 to $40.00 and set an “outperform” rating for the company in a research note on Wednesday, November 6th. Finally, Morgan Stanley initiated coverage on shares of Apellis Pharmaceuticals in a research report on Thursday, November 21st. They set an “equal weight” rating and a $31.00 price target on the stock. Eight research analysts have rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Apellis Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $46.71.

Institutional Investors Weigh In On Apellis Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of APLS. Wolverine Asset Management LLC purchased a new position in shares of Apellis Pharmaceuticals during the third quarter valued at about $27,000. True Wealth Design LLC bought a new stake in Apellis Pharmaceuticals during the 3rd quarter valued at approximately $27,000. Capital Performance Advisors LLP purchased a new position in shares of Apellis Pharmaceuticals during the 3rd quarter worth approximately $56,000. KBC Group NV raised its position in shares of Apellis Pharmaceuticals by 34.8% in the 3rd quarter. KBC Group NV now owns 2,632 shares of the company’s stock worth $76,000 after acquiring an additional 679 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Apellis Pharmaceuticals by 21.6% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,404 shares of the company’s stock valued at $130,000 after purchasing an additional 781 shares during the period. 96.29% of the stock is owned by hedge funds and other institutional investors.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).